{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:19:43Z","timestamp":1770063583174,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T00:00:00Z","timestamp":1154563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T00:00:00Z","timestamp":1154563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2006,10,1]]},"DOI":"10.1038\/sj.leu.2404333","type":"journal-article","created":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T13:35:58Z","timestamp":1154612158000},"page":"1683-1689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma"],"prefix":"10.1038","volume":"20","author":[{"given":"W I","family":"Bensinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,8,3]]},"reference":[{"key":"BF2404333_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ncponc0174","volume":"2","author":"S Kumar","year":"2005","unstructured":"Kumar S, Anderson KC . Drug insight: thalidomide as a treatment for multiple myeloma (review). Nat Clin Pract Oncol 2005; 2: 262\u2013270.","journal-title":"Nat Clin Pract Oncol"},{"key":"BF2404333_CR2","first-page":"214","volume-title":"Hematology 2002: American Society of Hematology Education Program Book","author":"KC Anderson","year":"2002","unstructured":"Anderson KC, Shaughnessy Jr JD, Barlogie B, Harousseau J-L, Roodman GD . Multiple myeloma. In: Broudy VC, Abkowitz JL, Vose JM (eds). Hematology 2002: American Society of Hematology Education Program Book. American Society of Hemtology: Washington, DC, 2002, pp 214\u2013240."},{"key":"BF2404333_CR3","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196\u20131198.","journal-title":"Blood"},{"key":"BF2404333_CR4","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","volume":"347","author":"LF Verdonck","year":"1996","unstructured":"Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ . Graft-versus-myeloma effect in two cases. Lancet 1996; 347: 800\u2013801.","journal-title":"Lancet"},{"key":"BF2404333_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","volume":"348","author":"J Aschan","year":"1996","unstructured":"Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G . Graft-versus-myeloma effect (letter). Lancet 1996; 348: 346.","journal-title":"Lancet"},{"key":"BF2404333_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/sj.bmt.1703253","volume":"28","author":"R Le Blanc","year":"2001","unstructured":"Le Blanc R, Montminy-M\u00e9tivier S, B\u00e9langer R, Busque L, Fish D, Roy D-C et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001; 28: 841\u2013848.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404333_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bmt.1701980","volume":"24","author":"J Libura","year":"1999","unstructured":"Libura J, Hoffmann T, Passweg J, Gregor M, Favre G, Tichelli A et al. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 925\u2013927.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404333_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/sj.leu.2400546","volume":"11","author":"H Bertz","year":"1997","unstructured":"Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J . adoptive immunotherapy for relapsed multiple myeloma after allogeniec bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997; 11: 281\u2013283.","journal-title":"Leukemia"},{"key":"BF2404333_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","volume":"26","author":"M Salama","year":"2000","unstructured":"Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A et al. donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179\u20131184.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404333_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"RH Collins Jr","year":"1997","unstructured":"Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433\u2013444.","journal-title":"J Clin Oncol"},{"key":"BF2404333_CR11","unstructured":"Alyea E, Ritz J . Induction of graft versus myeloma by donor lymphocyte infusions following allogeneic bone marrow transplant. In: Anderson KC (ed). VI International Workshop on Multiple Myeloma 1997, 1997."},{"key":"BF2404333_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/sj.bmt.1701459","volume":"22","author":"J Mehta","year":"1998","unstructured":"Mehta J, Singhal S . Graft-versus-myeloma (review). Bone Marrow Transplant 1998; 22: 835\u2013843.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404333_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","volume":"10","author":"N Kroger","year":"2004","unstructured":"Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698\u2013708.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF2404333_CR14","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","volume":"96","author":"F Dazzi","year":"2000","unstructured":"Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712\u20132716.","journal-title":"Blood"},{"key":"BF2404333_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/10428199809068567","volume":"29","author":"C Helg","year":"1998","unstructured":"Helg C, Starobinski M, Jeannet M, Chapuis B . Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation (review). Leukemia Lymph 1998; 29: 301\u2013313.","journal-title":"Leukemia Lymph"},{"key":"BF2404333_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0041-1345(98)01603-0","volume":"31","author":"R Storb","year":"1999","unstructured":"Storb R, Yu C, Sandmaier B, McSweeney P, Georges G, Nash R, Woolfrey A . Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplant Proc 1999; 31: 677\u2013678.","journal-title":"Transplant Proc"},{"key":"BF2404333_CR17","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390\u20133400.","journal-title":"Blood"},{"key":"BF2404333_CR18","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447\u20133454.","journal-title":"Blood"},{"key":"BF2404333_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","volume":"31","author":"C-K Lee","year":"2003","unstructured":"Lee C-K, Badros A, Barlogie B, Morris C, Zangari M, Fassas A et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003; 31: 73\u201380.","journal-title":"Exp Hematol"},{"key":"BF2404333_CR20","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood-2002-10-3250","volume":"102","author":"S Giralt","year":"2003","unstructured":"Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R . 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1\/2 trials. Blood 2003; 102: 2684\u20132691.","journal-title":"Blood"},{"key":"BF2404333_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","volume":"121","author":"H Einsele","year":"2003","unstructured":"Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411\u2013418.","journal-title":"Br J Haematol"},{"key":"BF2404333_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cncr.21700","volume":"106","author":"MH Qazilbash","year":"2006","unstructured":"Qazilbash MH, Saliba R, de Lima M, Hosing C, Couriel D, Aleman A et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106: 1084\u20131089.","journal-title":"Cancer"},{"key":"BF2404333_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ajh.20641","volume":"81","author":"F Elice","year":"2006","unstructured":"Elice F, Raimondi R, Tosetto A, D\u2019Emilio A, Di Bona E, Piccin A et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006; 81: 426\u2013431.","journal-title":"Am J Hematol"},{"key":"BF2404333_CR24","doi-asserted-by":"crossref","unstructured":"Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. 2002; 100: 755\u2013760.","DOI":"10.1182\/blood-2002-01-0131"},{"key":"BF2404333_CR25","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","volume":"100","author":"N Kroger","year":"2002","unstructured":"Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919\u20133924.","journal-title":"Blood"},{"key":"BF2404333_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.leukres.2005.01.017","volume":"29","author":"S Galimberti","year":"2005","unstructured":"Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005; 29: 961\u2013966.","journal-title":"Leuk Res"},{"key":"BF2404333_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","volume":"9","author":"KS Peggs","year":"2003","unstructured":"Peggs KS, Mackinnon S, Williams CD, D\u2019Sa S, Thuraisundaram D, Kyriakou C et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: 257\u2013265.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF2404333_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/sj.bmt.1704531","volume":"34","author":"M Mohty","year":"2004","unstructured":"Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404333_CR29","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","volume":"105","author":"C Crawley","year":"2005","unstructured":"Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of Prognostic Factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 105: 4532\u20134539.","journal-title":"Blood"},{"key":"BF2404333_CR30","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","volume":"107","author":"F Garban","year":"2006","unstructured":"Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474\u20133480.","journal-title":"Blood"},{"key":"BF2404333_CR31","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1182\/blood-2003-12-4435","volume":"103","author":"N Kroger","year":"2004","unstructured":"Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056\u20134061.","journal-title":"Blood"},{"key":"BF2404333_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.leu.2403252","volume":"18","author":"F Ayuk","year":"2004","unstructured":"Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18: 659\u2013662.","journal-title":"Leukemia"},{"key":"BF2404333_CR33","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2004-05-2031","volume":"104","author":"N Kroger","year":"2004","unstructured":"Kroger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361\u20133363.","journal-title":"Blood"},{"key":"BF2404333_CR34","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2005-11-4449","volume":"107","author":"NW van de Donk","year":"2006","unstructured":"van de Donk NW, Kr\u00f6ger N, Hegenbart U, Corradini P, Miguel JF, Goldschmidt H et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415\u20133416.","journal-title":"Blood"},{"key":"BF2404333_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929\u2013936.","journal-title":"J Clin Oncol"},{"key":"BF2404333_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","volume":"113","author":"G Gahrton","year":"2001","unstructured":"Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Bj\u00f6rkstand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation Centres. Br J Haematol 2001; 113: 209\u2013216.","journal-title":"Br J Haematol"},{"key":"BF2404333_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/sj.bmt.1701362","volume":"22","author":"I Majolino","year":"1998","unstructured":"Majolino I, Corradini P, Scim R, Santoro A, Tarella C, Cavallaro AM et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 449\u2013455.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404333_CR38","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood-2002-10-3250","volume":"102","author":"S Giralt","year":"2003","unstructured":"Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R et al. 166HO-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1\/2 trials. Blood 2003; 102: 2684\u20132691.","journal-title":"Blood"},{"key":"BF2404333_CR39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/sj.leu.2403575","volume":"19","author":"A Dispenzieri","year":"2005","unstructured":"Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA et al. A Phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005; 19: 118\u2013125.","journal-title":"Leukemia"},{"key":"BF2404333_CR40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/sj.leu.2403698","volume":"19","author":"GA Kennedy","year":"2005","unstructured":"Kennedy GA, Durrant S, Butler J, Morton J, Western R, Bartlett ML et al. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Leukemia 2005; 19: 879\u2013880.","journal-title":"Leukemia"},{"key":"BF2404333_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1056\/NEJM200101183440303","volume":"344","author":"WI Bensinger","year":"2001","unstructured":"Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175\u2013181.","journal-title":"N Engl J Med"},{"key":"BF2404333_CR42","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/00006231-200211000-00010","volume":"23","author":"DJ Macfarlane","year":"2002","unstructured":"Macfarlane DJ, Durrant S, Bartlett ML, Allison R, Morton AJ . 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 2002; 23: 1099\u20131106.","journal-title":"Nucl Med Commun"},{"key":"BF2404333_CR43","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","volume":"100","author":"HJ Deeg","year":"2002","unstructured":"Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201\u20131207.","journal-title":"Blood"},{"key":"BF2404333_CR44","first-page":"939","volume":"23","author":"R Champlin","year":"1995","unstructured":"Champlin R, Giralt S, Gajewski J, Hester J, K\u00f6rbling M, Deisseroth A . CD8 depleted donor lymphocytes for CML relapsing post BMT. Int Soc Exp Hematol 1995; 23: 939.","journal-title":"Int Soc Exp Hematol"},{"key":"BF2404333_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","volume":"129","author":"N Kroger","year":"2005","unstructured":"Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A et al. Comparison between antithymocyte globulin, alemtuzumab, the possible impact of KIR-ligand mismatch after dose-reduced conditioning, unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129: 631\u2013643.","journal-title":"Br J Haematol"},{"key":"BF2404333_CR46","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bmt.1705161","volume":"36","author":"S Gerull","year":"2005","unstructured":"Gerull S, Goerner M, Benner A, Hegenbart U, Klein U, Schaefer H et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36: 963\u2013969.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404333_CR47","first-page":"77","volume":"10","author":"SY Ma","year":"2004","unstructured":"Ma SY, Lie AK, Au WY, Chim CS, Kwong YL, Liang R . Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma. Hong Kong Med J 2004; 10: 77\u201383.","journal-title":"Hong Kong Med J"},{"key":"BF2404333_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1365-2141.2003.04237.x","volume":"121","author":"J Perez-Simon","year":"2003","unstructured":"Perez-Simon J, Martino R, Alegre A, Tomas J, De Leon A, Caballero D et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104\u2013108.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404333","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:27:32Z","timestamp":1648780052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,3]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10,1]]}},"alternative-id":["BF2404333"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404333","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,3]]},"assertion":[{"value":"22 May 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}